Experimental antiviral COVID-19 treatment pill, molnupiravir, developed by Merck & Co Inc and partner Ridgeback Biotherapeutics LP, presents promising results in halving the chances of dying or being hospitalized from COVID-19. If authorized, the pill would be the first oral antiviral treatment for COVID-19, with the aim of introducing errors into the genetic code of the virus. The drug makers plan to seek US FDA approval as soon as possible, with researchers calling the drug a potential gamechanger in treating those with severe COVID-19 disease. Phase III trials are also currently testing molnupuravir’s effectives in preventing infection for people exposed to the virus.
Learn more here.